Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and Facilitated Extinction for Smoking Cessation
NCT02202499Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varenicline in tobacco dependence, sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Participant Retention at 28 weeks. Started Jul 2014; status: completed.
02
Drugs
varenicline
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT02202499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202499.